The most interesting shift in anti-ageing is that the science finally became more ambitious than the marketing — and then the label rules stopped both. “Skin longevity” asks a genuinely different question from anti-wrinkle skincare: not how to soften a visible line, but how to keep skin functioning well for longer. Suppliers across the region have reorganised their 2026 pitches around it, and the underlying biology is real work, not a slogan. What almost nobody sends with the pitch deck is the part that decides whether the product can ship: in Malaysia, most of the words that make longevity sound compelling are on the regulator’s unacceptable-claims list. This piece is about that gap, and how a brand buys around it.
Written and researched by Marcus Tan, Private Label & Beauty Sourcing Consultant · Article type: Independent Editorial · Scope: commercial, claims and sourcing implications of the skin-longevity direction in personal care, with Malaysian, ASEAN and European Union reference points · Research period: August 2026 · Last reviewed: August 2026 · Corrections: via the site contact page.
Quick answer: can a brand actually sell “skin longevity”?
A brand can build and sell a skin-longevity product, but in Malaysia it generally cannot describe it in longevity language. The National Pharmaceutical Regulatory Agency (NPRA) lists references to cell renewal, DNA repair, skin metabolism, collagen and elastin production, and to preventing, reducing or reversing the ageing process as unacceptable cosmetic claims — while “slows down or delays signs of ageing” is acceptable. The practical consequence is that longevity is a formulation and evidence strategy, not a label strategy. Before approving artwork, run every proposed phrase against Annex I Part 8 of the Malaysian cosmetic guidelines rather than against the supplier’s marketing brochure.
Key takeaways
- Skin longevity has a real scientific frame behind it. A 2025 review in Frontiers in Aging proposed the first peer-reviewed definition of a “longevity cosmeceutical” — a product that modulates established hallmarks of skin ageing and demonstrably extends “skinspan” — and mapped twelve ageing hallmarks onto skin.
- The same review is blunt about the marketing: the term appears in commercial narratives but “remains undefined and unsupported by peer-reviewed scientific literature.” A brand quoting the trend is not quoting a settled standard.
- Malaysia’s claims guideline makes most longevity vocabulary unusable. Cell regeneration, DNA repair, skin metabolism, collagen and elastin synthesis, increased cell turnover and “younger looking skin” are all listed as unacceptable for cosmetic skin products.
- The word “cosmeceutical” is itself an unacceptable claim in Malaysia, as are graphics or logos referring to substances of human origin such as growth factors (EGF, FGF) — which cuts directly across how several longevity actives are marketed upstream.
- Claim decision point five is the one that matters: a product that permanently restores, corrects or modifies physiological function by pharmacological, immunological or metabolic action is not a cosmetic at all. Longevity storytelling walks towards that line by design.
- Quantitative claims — a percentage, a number of days, a multiple — remain acceptable in Malaysia if substantiated. That, not mechanism language, is where a longevity budget should go.
- The cost of a longevity project sits in evidence, not ingredients. Biopsy-supported or biomarker-supported testing is a different order of expense from a standard consumer-perception panel, and it is usually absent from the first quotation.
Who this is for
This is written for brand founders, private label buyers and category managers who have been shown a skin-longevity concept — by a supplier, a distributor or their own marketing team — and now have to decide what to commission, what to pay for and what the carton may say. It is a commercial and claims view rather than a formulation tutorial. If you are still choosing a partner rather than briefing one, start with our guide to evaluating an OEM skincare manufacturer; if the product is still a concept, what custom formulation actually involves sets the expectations this article assumes.
What does “skin longevity” actually mean scientifically?
Skin longevity reframes ageing as a set of biological mechanisms to be slowed rather than a set of visible marks to be covered. The vocabulary comes from geroscience, where ageing is described through hallmarks — genomic instability, telomere attrition, epigenetic alteration, loss of proteostasis, mitochondrial dysfunction, cellular senescence, deregulated nutrient sensing, chronic inflammation, altered intercellular communication, stem cell exhaustion and dysbiosis among them. The 2025 Frontiers in Aging review by Klinngam and colleagues took that framework and applied it to skin, proposing that a product deserving the longevity description should modulate those hallmarks and extend what the authors call skinspan: sustained skin viability, structure and function over time.
That is a materially higher bar than the anti-ageing category has historically used, and it comes with a matching test burden. The review’s proposed substantiation route runs through three-dimensional reconstructed and ex vivo skin models measuring viability and structural integrity, hallmark-specific biomarkers such as senescence-associated beta-galactosidase, and randomised clinical trials that pair conventional endpoints — hydration, elasticity, wrinkle depth — with post-treatment skin biopsies and epigenetic ageing clocks. Read as a purchase order rather than a paper, that is a research programme, not a product development timeline.
The honest reading of the trend is therefore two-sided. The mechanistic direction is credible and the ingredient pipeline behind it — polyphenols, peptides, fermentation-derived actives, polydeoxyribonucleotide (PDRN) and exosome-inspired materials — is where genuine supplier investment is going. But the category label is running ahead of its own evidence base, and the researchers proposing the framework say so in the same paper. A brand that treats “longevity” as an established, defined and defensible standard is quoting something that does not exist yet.
Why most longevity language cannot go on a Malaysian label
Because Malaysia’s cosmetic claims guideline names, almost line for line, the exact mechanisms that longevity marketing is built on. Annex I Part 8 of the Guidelines for Control of Cosmetic Products in Malaysia sets out a five-step decision process for whether a proposition is a cosmetic at all, then gives worked examples of acceptable and unacceptable claims by product type. For skin products, the unacceptable column reads like a summary of the longevity pitch deck.
| Longevity marketing phrase | Status in Malaysia (Annex I Part 8) | What may be said instead |
|---|---|---|
| “Stimulates collagen and elastin production” | Unacceptable — reference to production of collagen and elastin | Firming; improves the appearance of firmness; reduces the appearance of wrinkles |
| “Supports DNA repair” / “protects the genome” | Unacceptable — reference to DNA repair | Helps protect skin from the visible effects of environmental stress |
| “Boosts cellular metabolism / mitochondrial energy” | Unacceptable — reference to skin metabolism | Helps skin look revitalised and less tired |
| “Regenerates cells” / “renews skin at cellular level” | Unacceptable — nourish, rejuvenate or regenerate cell; accelerate skin renewal; increase cell turnover | Smoothes skin texture; improves the appearance of skin surface renewal |
| “Reverses the ageing process” / “turns back biological age” | Unacceptable — prevent, reduce, reverse or delay the ageing process | Slows down or delays signs of ageing (explicitly acceptable) |
| “Younger looking skin” | Unacceptable in the Malaysian examples list | Reduces the appearance of fine lines, dark spots and pigmentation |
| “Improves microcirculation to feed the skin” | Unacceptable — reference to blood circulation or microcirculation | Helps skin look brighter and more even in tone |
| “A longevity cosmeceutical” | Unacceptable — “cosmeceutical” is listed among disallowed terms | Advanced skincare; clinically tested skincare (if the testing exists) |
| Growth-factor iconography (EGF, FGF), cell diagrams | Unacceptable — graphics, logos or symbols referring to internal organs, body parts or substances of human origin, including growth factors | Abstract or ingredient-led visual language |
| “Clinically proven to reduce wrinkle depth by 23% in 28 days” | Acceptable if substantiated — quantitative claims such as 99.9%, in 3 days or 10x are permitted with relevant evidence | Keep it, and hold the study that supports it |
Table compiled for this article from NPRA Guidelines for Control of Cosmetic Products in Malaysia, Annex I Part 8 (August 2022). The guideline states it is not exhaustive and that NPRA may disallow other wording it considers misleading. Compliant alternatives are editorial suggestions, not approved wording.
Read that table twice and the commercial logic inverts. The claim that survives is not the mechanistic one; it is the measured one. “Slows down signs of ageing” plus a substantiated number outperforms “reverses cellular ageing” with nothing behind it — legally, and increasingly with consumers who have learned to discount mechanism language. This is the same pattern we described in our analysis of clean and sustainable claims: the regulator does not object to ambition, it objects to unsupported specificity in the wrong register.
The question that decides whether it is still a cosmetic
The fifth step in Malaysia’s decision process asks whether the product permanently restores, corrects or modifies physiological function by exerting a pharmacological, immunological or metabolic action. If the answer is yes, the proposition is not a cosmetic, and the conversation moves to an entirely different registration pathway. The guideline is explicit that cosmetic effects are typically not permanent and must be maintained by regular use.
Longevity narratives are built, deliberately, to sound like the opposite of that. Language about resetting biological age, clearing senescent cells or permanently altering how skin behaves is exactly the register the fifth question is designed to catch. Note also that the assessment does not stop at the carton: the guideline directs the regulator to consider promotional literature, third-party testimonials, advertisements, product form and the specific audience being targeted. A compliant label undermined by an ambitious founder interview or an affiliate’s video is a real and common failure mode, and it is one that a manufacturer cannot control on the brand’s behalf.
For brands selling into Europe as well, the parallel constraint is Commission Regulation (EU) No 655/2013, which lays down the common criteria for cosmetic product claims — legal compliance, truthfulness, evidential support, honesty, fairness and informed decision-making. It does not publish a Malaysian-style banned-phrase list, so the two regimes fail differently: Malaysia will tell you which words are wrong, while the EU will ask you to produce the substantiation dossier behind whatever words you chose. A brand selling into both is designing to the union of the two, which in practice means conservative wording plus a real evidence file.
What evidence does a longevity claim actually require?
Match the evidence tier to the claim tier, and budget before the artwork is signed rather than after. The reason longevity projects overrun is that the ingredient conversation happens months before anyone prices the study that the intended claim will need.
| Claim tier | Typical wording | Evidence normally expected | Where it usually goes wrong |
|---|---|---|---|
| Sensory / appearance | Smoother, more supple, radiant | Consumer perception panel with a defined protocol and sample size | Panel too small, or run on a different formula version than the one filled |
| Instrumental | Improves elasticity; reduces wrinkle depth | Instrumental measurement (cutometry, profilometry, corneometry) against baseline or control | No control arm, so the result cannot be attributed to the product |
| Quantified | 23% reduction in 28 days | The instrumental study, plus statistics that actually support the stated figure | The number is taken from the supplier’s active-ingredient study, not the brand’s finished formula |
| Mechanistic / longevity | Modulates senescence; supports skinspan | Ex vivo or reconstructed skin models, hallmark biomarkers, ideally biopsy-supported clinical work | Even when the evidence exists, the claim wording remains unusable on a Malaysian label |
The distinction in row three is the single most expensive misunderstanding in this category. An active supplier’s dossier documents what the raw material did at a specified concentration in a specified test vehicle. It is not evidence about a brand’s finished product at the concentration the brand could afford, in the base the brand chose, with the fragrance and preservative system the brand approved. Transferring a number across that gap is how brands end up unable to defend a figure they printed. Our checklist of tests to complete before a first batch covers the sequencing; the point here is narrower and financial — the study belongs in the launch budget, not in a later phase.
Three of the actives currently carrying this trend illustrate why the evidence question is unavoidable. Structural actives aimed at the dermal matrix, encapsulated peptide systems and biotech-derived collagen fragments each arrive with a mechanistic story attached, and each of those stories describes a mechanism Malaysia will not let a label state. We have looked at individual examples in this space — a structural skin-longevity active, an encapsulated peptide and an AI-designed collagen III material — and the pattern repeats: strong supplier science, and a translation problem that lands on the brand.
What this changes in a sourcing conversation
It moves claims from the end of the project to the beginning. In a conventional skincare brief, wording is drafted once the formula is stable; in a longevity brief, the wording determines whether the formula is worth developing at all. If the only claim that justifies the price premium is one the label cannot carry, the concept fails commercially before it fails technically — and it is cheaper to discover that in week two than in month seven.
Three practical consequences follow for the way a brief is written. First, name the target markets in the brief itself, because Malaysia’s explicit phrase list, the EU’s substantiation-first common criteria and other ASEAN member states’ interpretations will not converge on the same carton. Second, ask for the claim to be quoted alongside the formula: a manufacturer that has filed Malaysian notifications in this category knows which phrasings have passed and which have been challenged, and that operational knowledge is worth more than a compliance opinion. Third, budget the substantiation study as a line item with a named laboratory and a date, not as a contingency — because the number is the claim that survives, and the number has to come from somewhere.
There is also a positioning opportunity in the constraint. Because the acceptable Malaysian phrasing is deliberately modest — slows down and delays signs of ageing, improves the appearance of firmness — the differentiation has to come from substantiated specifics and from the honesty of the timeline. A brand that says exactly what it measured, over exactly how long, in exactly how many subjects, is more credible in 2026 than one promising cellular renewal, and it is also the version that survives a regulatory review, a marketplace listing check and a journalist with a copy of the guideline.
Red flags and questions to ask before you commission
The warning signs in this category are specific enough to check in a single meeting. Watch for a supplier that quotes mechanism claims without ever mentioning the label, one that offers the active’s study as if it were the product’s study, or one that answers a claims question with reassurance rather than with a notification history. Watch equally for an internal marketing plan that has already written the launch copy in longevity language before anyone has read Annex I Part 8.
- Which of these exact phrases have you filed successfully in Malaysia, and which were queried? The answer separates operational experience from a compliance leaflet.
- Is the efficacy data on this active, or on my finished formula at my concentration? Ask for the test vehicle, the concentration and the date on the report.
- What does the substantiation study cost, which laboratory runs it, and how long does it take? Get this before signing, not at artwork stage.
- If I change the fragrance, the preservative or the pack, what has to be repeated? Every change has a re-test consequence; find out which ones are expensive.
- Who reviews my social, influencer and packaging-insert copy against the guideline? The regulator assesses promotional material, not only the carton.
- What is the acceptable wording you would put on this product today? A partner who can draft compliant copy on the spot has done this before.
Frequently asked questions
Is “anti-ageing” itself banned in Malaysia?
No. What is unacceptable is claiming to prevent, reduce, reverse or delay the ageing process; the guideline explicitly lists “slows down or delays signs of ageing” as acceptable. The distinction is between the biological process and its visible signs, and it runs through the whole guideline — appearance-level wording generally survives, mechanism-level wording generally does not. Check your proposed phrase against the worked examples in Annex I Part 8 before the artwork is approved.
Can I use the word “cosmeceutical” if my product genuinely has clinical data?
Not in Malaysia. The term appears in NPRA’s unacceptable-claims list alongside mesotherapy, injection and micro-needling references, regardless of the evidence behind the product. If you hold clinical data, describe the study and its result — a substantiated quantitative claim is permitted — rather than reaching for a category label the regulator has already ruled out.
My supplier’s active has published research on senescence. Can I say that?
You can hold it in your dossier; you generally cannot put it on the label or in consumer-facing promotion in Malaysia, because it is mechanism language of exactly the kind the guideline restricts. There is also a substantiation problem underneath the wording problem: research on an ingredient is not evidence about your finished product. Use the ingredient story in trade and technical contexts, and let a measured consumer-facing result carry the marketing.
Does this apply to supplements marketed for skin longevity?
No — ingestible products fall outside the cosmetic definition entirely, because a cosmetic must be applied to defined external parts of the body and products intended to be ingested or injected cannot be considered cosmetic products. Beauty-from-within formats sit under a different regulatory regime with its own claim rules, so a brand running a topical and an ingestible under one longevity story is managing two separate claim frameworks and should brief them separately.
How much does substantiating a longevity claim realistically add to a project?
It varies too widely by claim tier, market and laboratory for a single figure to be honest, but the shape is consistent: a consumer-perception panel is the cheapest tier, instrumental testing with a control arm sits materially above it, and biomarker or biopsy-supported work is a different order of expense that most brands at launch scale do not carry. Ask three laboratories for a quotation against your exact intended wording before you commit to the wording — the cost of the study is what determines whether the claim is affordable.
Sources and evidence
- National Pharmaceutical Regulatory Agency (NPRA), Guidelines for Control of Cosmetic Products in Malaysia, Annex I Part 8 — Guideline for Cosmetic Claims (August 2022): the five-step decision process, the acceptable and unacceptable claim examples by product type, and the rules on GMP, safety and quantitative claims.
- Klinngam W. et al., “Longevity cosmeceuticals as the next frontier in cosmetic innovation: a scientific framework for substantiating product claims”, Frontiers in Aging 6:1586999 (2025): the proposed definition, the hallmarks-of-ageing framework applied to skin, the substantiation methodology and the caution that the term remains undefined in the literature.
- Commission Regulation (EU) No 655/2013 laying down common criteria for the justification of claims used in relation to cosmetic products, read with Article 20 of Regulation (EC) No 1223/2009.
- López-Otín C. et al., “Hallmarks of aging: An expanding universe”, Cell (2023): the twelve-hallmark framework that the skin-longevity literature builds on.
- Claim-status readings in the comparison table are this publication’s interpretation of the NPRA examples list. The guideline states it is not exhaustive and that the regulator may disallow other wording; treat the table as a starting point for a conversation with your notification holder, not as clearance.
Source / inspired by: the theme of this article — that anti-ageing in 2026 is shifting from surface correction towards biological longevity, supported by actives such as PDRN, exosome-inspired materials, polyphenols and peptides — is drawn from Azelis Personal Care’s inspiration material. See Skin longevity and wellness focus in Personal Care and the Azelis Personal Care inspiration hub. The regulatory analysis, comparison tables and commercial conclusions here are independent.
Further reading: for the manufacturing side of the same question — what a longevity brief changes inside a contract manufacturer — see A Skin Longevity Brief Is a Claims Decision Before It Is a Formula, written from a contract manufacturer’s operations perspective.
Limitations and scope
This is a desk-based commercial and claims analysis, not laboratory or legal work. No product was tested for this article, no supplier documentation was audited, and no claim wording here has been cleared by any regulator. The Malaysian positions are summarised from the primary guideline linked above as published in August 2022; NPRA states the examples list is not exhaustive and is subject to review, and notification outcomes depend on the complete product proposition rather than on a phrase in isolation. The European position is summarised at the level of the common criteria and does not address member-state advertising rules, which are stricter in several markets. Costs, timelines and test requirements described here are general category patterns and vary by product format, claim tier, target markets and laboratory. Verify all claim wording with your notification holder and the relevant authority for each market before committing to artwork.
Update history
| Date | Change |
|---|---|
| 27 August 2026 | First published. |
This article is independent editorial research written to help brand owners ask better questions of prospective manufacturers. It does not rank, endorse or recommend any specific supplier or ingredient, and no product mentioned was tested by this publication. Verify claim wording, substantiation requirements and notification status directly with your manufacturer and the relevant regulator for each market you sell in.